Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Definitions

• X is H or halogen
• their therapeutic use in the treatment of edema, hypotension, cardiac insufficiency and mucosa hypermia discloses such a compound, i.e. 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole. It is described as a sympathomimetic agent resulting from direct adrenergic alpha stimulation, and Ohnishi et al conclude that it is of potential use for the treatment of hypotensive disorders.
• 2-[(5-Chloro-2-methoxyphenyl)azo]-1 H-imidazole is currently considered to be a non-subtype-selective alpha 1 adrenoceptor agonist (hereafter "alpha agonist"; see Tocris catalogue 2001 of Tocris Cookson Ltd., Bristol, UK, Table 1 , page 20).
• alpha agonist non-subtype-selective alpha 1 adrenoceptor agonist
• the compound is referred to in this catalogue as a hypertensive agent (page 243) and is commercially available from Tocris as a research tool. Considerations as to the selectivity of the compound are based on published studies using laboratory animal species.
• Alpha 1 agonists in general cause smooth muscle contraction and thereby increase smooth muscle tone, for example in blood vessels or in the lower urinary tract.
• the alpha 1 receptors are currently divided into 4 subtypes, these being alpha 1 A, alpha 1 L (possibly a related receptor), alpha 1 B and alpha 1 D.
• alpha 1 A alpha 1 A
• alpha 1 L possibly a related receptor
• alpha 1 B alpha 1 D
• different tissues may contain a predominance of a particular alpha 1 receptor subtype. It is also known that there is a marked species dependency in the tissue distribution of adrenergic alpha 1 subtypes.
• adrenergic alpha stimulatory activity may be determined by known assays, and is preferably at least substantially as for noradrenaline. This activity is preferably at least 50% of the activity exhibited by 2-[(5-chloro-2-methoxyphenyl)azo]-1 H-imidazole.
• Preferred agents for use in the invention have one or more structural characteristics of the formula shown above.
• the active compound can be formulated in any suitable manner, together with a conventional diluent or carrier, e.g. as a tablet or capsule, or as a sustained release formulation.
• the active compound may be administered by any suitable route, e.g. intravaginal (for which purpose a pessary or ring device may be used), and is preferably administered by the oral route.
• compositions for oral use include tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups and elixirs.
• Suitable additives include sweetening agents, flavouring agents, colouring agents and preserving agents. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients, e.g.
• inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
• the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastointestinal tract and thereby provide a sustained action over a longer period.
• a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
• Hard gelatin capsules may include an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin; soft gelatin capsules may include water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
• the amount of active agent to be administered can be readily determined by the skilled person, and will depend on the usual factor such as the frequency of dosing, the age and condition of the patient, the nature and degree of the complaint, the rate of administration, coadministered drugs etc.
• a typical daily dosage may be 0.1-1000, e.g. 1-100, mg.
• Tissue sources human lower urinary tract smooth muscle strips (prostatic/urethral) were obtained from patients undergoing transurethral resection of the prostate procedure for benign prostatic hyperplasia.
• Human mesenteric arte ⁇ es 500-750 ⁇ m internal diameter were obtained from patients undergoing bowel resection for carcinoma.
• Tissues were preserved in Krebs-bicarbonate solution at 4°C from the time of surgery until used in functional experiments within 24 hours. Protocol Sections of mesenteric artery (5 mm in length) were set up between stainless steel stirrups after removal of the endothelium by gentle rubbing.
• LUT 2-[(5-chlo ⁇ 2-methoxyphenyl)azo]-1 H-imidazole is at least as potent as noradrenaline with a similar maximum effect.

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Diabetes (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9916211

Family Applications (1)

Country Status (13)

Citations (2)

Family Cites Families (1)

• 2001
  • 2001-06-08 GB GBGB0114008.6A patent/GB0114008D0/en not_active Ceased
• 2002
  • 2002-06-07 KR KR10-2003-7015978A patent/KR20040030654A/ko not_active Withdrawn
  • 2002-06-07 EP EP02738362A patent/EP1399167A1/en not_active Withdrawn
  • 2002-06-07 ZA ZA200309473A patent/ZA200309473B/xx unknown
  • 2002-06-07 CA CA002449957A patent/CA2449957A1/en not_active Abandoned
  • 2002-06-07 CN CNB028129687A patent/CN1234367C/zh not_active Expired - Fee Related
  • 2002-06-07 US US10/478,977 patent/US20040242547A1/en not_active Abandoned
  • 2002-06-07 AU AU2002311445A patent/AU2002311445B2/en not_active Ceased
  • 2002-06-07 JP JP2003503235A patent/JP2005500285A/ja not_active Withdrawn
  • 2002-06-07 WO PCT/GB2002/002635 patent/WO2002100414A1/en not_active Ceased
  • 2002-06-07 RU RU2004100228/15A patent/RU2004100228A/ru not_active Application Discontinuation
  • 2002-06-07 BR BR0210195-5A patent/BR0210195A/pt not_active IP Right Cessation
  • 2002-06-07 MX MXPA03011226A patent/MXPA03011226A/es unknown

Patent Citations (2)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events